Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
GlycoMimetics fails phase 3 blood cancer trial, sinking stock
GlycoMimetics CEO Harout Semerjian said in March that phase 3 blood cancer data could “fundamentally impact our company's trajectory.” He was right.
Nick Paul Taylor
May 6, 2024 8:11am
CG sets new bar in bladder cancer, months after huge IPO
May 3, 2024 11:23am
Jacobio's KRAS data tee up safety-focused lung cancer pitch
May 1, 2024 7:01am
NRx keeps antidepressant's blockbuster hopes alive despite flop
Apr 30, 2024 11:16am
Newron schizophrenia add-on improves positive, negative symptoms
Apr 30, 2024 9:13am
Annovis shares plummet 60% after muddled Alzheimer’s readout
Apr 29, 2024 11:45am